Best peptides for Lyme disease FAQ

This is PTLDS—post-treatment Lyme disease syndrome. The standard medical response is 'wait it out,' but immune dysregulation doesn't resolve spontaneously in many cases. Start with Thymalin to restore T-cell function—10mg subcutaneous injections every 48 hours for 10 doses. Pair this with oral KPV (500 mcg daily) to reduce residual inflammation. If cognitive symptoms dominate, add Cerebrolysin 5mL IV daily for 20 sessions under medical supervision. Monitor cytokine panels and lymphocyte subsets before and after—meaningful improvement takes 4–8 weeks.

Intestinal permeability is common in chronic Lyme—inflammatory cytokines damage tight junctions, allowing bacterial endotoxins into circulation. Use oral KPV as first-line: 500 mcg daily targets intestinal NF-κB directly. Add BPC-157 (250 mcg SubQ daily) for systemic repair—its angiogenic effects restore microcirculation to damaged gut epithelium. Expect noticeable gut symptom reduction within 2–3 weeks; full barrier restoration takes 8–12 weeks.

Neuroborreliosis-associated brain fog and memory lapses reflect hippocampal damage from microglial activation. Cerebrolysin is the most evidence-backed option—5–10mL IV daily for 20 sessions delivers BDNF and NGF directly to damaged neural tissue. Dihexa shows stronger preclinical synaptogenesis data but lacks human dosing protocols. MK-677 (25mg oral nightly) supports overall recovery by elevating IGF-1, which promotes neuroplasticity. Cognitive improvement is gradual—meaningful gains appear at 6–8 weeks, peak at 12–16 weeks.

Relapse within 6–12 months post-treatment suggests either residual persister spirochetes or established immune dysfunction maintaining symptoms independently. LL-37 2–5mg daily for 4–6 weeks addresses potential persister populations through membrane disruption mechanisms—unlike antibiotics, LL-37 kills metabolically dormant bacteria. If symptoms persist beyond LL-37 treatment, shift focus to immune restoration with Thymalin or Thymosin Alpha-1—at that point, immune dysregulation is the driver, not residual infection.

Elevated C-reactive protein, ESR, or pro-inflammatory cytokines (TNF-alpha, IL-6) six months post-antibiotic suggest immune dysregulation, not active infection. KPV 500–1000mcg daily addresses NF-κB-driven inflammation, particularly if gut symptoms (bloating, irregular bowel movements) persist—gut barrier dysfunction perpetuates systemic inflammation through endotoxin translocation. Combine with VIP 100–200mcg intranasally twice daily if neurological symptoms (brain fog, memory issues, mood changes) dominate the clinical picture—VIP crosses the blood-brain barrier and reduces neuroinflammation through macrophage M2 polarization.

Start with Thymalin 5–10mg daily for 10 days to restore thymic output. Thymalin directly stimulates thymic epithelial cells, increasing naive T-cell production—the long-term solution for depleted T-cell populations. Follow initial loading with maintenance dosing 2–3 times weekly for 8–12 weeks while monitoring CD4+/CD8+ ratios monthly. Add Thymosin Alpha-1 1.6mg twice weekly if NK cell activity assays show suppression below 15 lytic units—Thymosin Alpha-1 increases NK cytotoxicity 30–50% within 2–4 weeks.

Normal inflammatory markers with persistent symptoms suggest tissue-level inflammation not captured by systemic markers—cytokine imbalances within joints, nervous tissue, or muscle compartments. VIP shows efficacy in localized inflammatory conditions through macrophage reprogramming, reducing tissue inflammation without systemic immunosuppression. Combine with gut barrier restoration protocols (L-glutamine, zinc carnosine, probiotics)—gut permeability perpetuates low-grade inflammation even when serum markers normalize.